Xu et al. identified 34 key therapeutic targets for T2DM associated with nonalcoholic fatty liver disease (NAFLD), including IL6, IL1B, VEGFA, PTGS2, and CCL2. Here, VEGFA is linked to metabolic dysfunction-associated steatotic liver disease.